Stryker Corporation (SYK) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 30, 2026 and Stryker published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Stryker reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Stryker reorganized its businesses in Q1 2026: Ortho Tech now combines orthopaedic instruments with Other Orthopaedics, and Neuro Cranial and spine enabling technologies moved into Instruments. Stryker recast all earlier periods.
• Q3 2026 GAAP results include a $293 million goodwill impairment for the Peripheral Vascular business, which is not tax deductible.
• Q2 2026 GAAP EPS of $3.30 included a $0.34 benefit from the reversal of 2025 tariffs, which Stryker excludes from adjusted EPS. A cybersecurity incident first reported on March 11, 2026 caused idle production time in Q1 2026.

Source: Stryker Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Stryker splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Stryker's MedSurg and Neurotechnology revenue was $3.7 billion in Q3 2026, up 9% from $3.4 billion in Q3 2025, 56% of total revenue.
• Stryker's Orthopaedics revenue was $2.9 billion in Q3 2026, up 6% from $2.7 billion in Q3 2025, 44% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Stryker said:

“We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range of $14.80 to $14.90.”

“Our sales guidance includes a modestly positive pricing impact.”

Source: Stryker Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the SYK forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Net sales and GAAP diluted EPS, each as first reported in that quarter's release.

Stryker's next report is expected around January 28, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Stryker reports two segments. In Q3 2026 MedSurg and Neurotechnology brought in $3,664 million of the $6,520 million total and Orthopaedics $2,856 million. MedSurg covers Instruments, Endoscopy, Medical and Vascular; Orthopaedics covers Knees, Hips, Trauma and Extremities and Ortho Tech. (Stryker Q3 2026 release, Oct 29, 2026)

Stryker's sales rose 7.7% on a reported, constant currency and organic basis alike, which Stryker attributes primarily to increased unit volume. MedSurg and Neurotechnology grew 9.2% (9.1% organic) and Orthopaedics 5.7% (5.9% organic). (Stryker Q3 2026 release, Oct 29, 2026)

Endoscopy was the fastest-growing large business, up 13.9% to $1,021 million, and Ortho Tech rose 15.8% to $754 million. Knees grew 1.1% and Hips fell 1.0%. In the U.S., Vascular sales rose 13.0%, while international Vascular sales rose only 2.1%. (Stryker Q3 2026 release, Oct 29, 2026)

The United States accounted for $4,950 million of Stryker's Q3 2026 sales, up 8.3%, and international markets for $1,570 million, up 5.7%. Stryker expects segment mix to weigh on gross margin, because it anticipates faster growth in the lower-margin MedSurg and Neurotechnology segment than in Orthopaedics. (Stryker Q3 2026 release, Oct 29, 2026; Stryker Form 10-Q, Q3 2026, Oct 30, 2026)

Stryker's GAAP EPS fell 11.7% to $1.96 while adjusted EPS rose 10.3% to $3.52 in Q3 2026. The gap of $1.56 a share is mostly a $293 million goodwill impairment on the Peripheral Vascular business ($0.76), amortization of purchased intangibles ($0.37) and structural optimization and other special charges ($0.20), including costs tied to the sale of Spinal Implants. (Stryker Q3 2026 release, Oct 29, 2026; Stryker Form 10-Q, Q3 2026, Oct 30, 2026)

Stryker said the Peripheral Vascular impairment reflected lower forecast cash flows from near-term operational and supply constraints and a longer expected period to reach anticipated growth. Because the charge is not tax deductible, Stryker's effective tax rate rose to 24.5% from 16.5%; the adjusted rate was 16.0%. (Stryker Form 10-Q, Q3 2026, Oct 30, 2026; Stryker Q3 2026 release, Oct 29, 2026)

Stryker repurchased $1.0 billion of its stock in Q3 2026, and in October its board added $3.0 billion to the existing buyback program. Diluted shares were 384.7 million, against 386.7 million a year earlier. (Stryker Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Stryker gives full-year guidance in its release, in organic sales growth and adjusted EPS. With Q3 2026 it updated its 2026 outlook to organic net sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90, with a modestly positive pricing impact and a slightly favorable effect from foreign exchange if rates hold. (Stryker Q3 2026 release, Oct 29, 2026)

Stryker's CEO said the quarter's 7.7% organic growth fell short of Stryker's expectations, and that Stryker expects a solid performance in Q4. Stryker gives no GAAP EPS outlook, saying it cannot predict charges such as structural optimization costs and legal and tax matters. (Stryker Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Stryker, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Stryker's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning SYK is on is SYK a buy or a sell?, what analysts expect next is on the SYK forecast, and what the company does is on the Stryker Corporation (SYK) stock page.

Every number on this page can be traced to a document Stryker published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.